Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,389
  • Shares Outstanding, K 5,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,910 K
  • 60-Month Beta -0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NERV with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 185.66%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.35
  • Number of Estimates 1
  • High Estimate -1.35
  • Low Estimate -1.35
  • Prior Year -0.96
  • Growth Rate Est. (year over year) -40.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.43 +62.31%
on 01/03/23
2.99 -22.41%
on 01/11/23
+0.73 (+45.91%)
since 12/30/22
3-Month
1.26 +84.13%
on 12/29/22
3.96 -41.41%
on 11/09/22
-0.44 (-15.94%)
since 10/28/22
52-Week
1.26 +84.13%
on 12/29/22
15.27 -84.81%
on 08/31/22
-3.44 (-59.70%)
since 01/28/22

Most Recent Stories

More News
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

CANF : 4.12 (+1.23%)
NERV : 2.32 (-1.69%)
AMLX : 38.68 (-5.50%)
ACER : 2.27 (-3.81%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.5000 (unch)
MRVL.VN : 0.100 (unch)
SAGE : 43.15 (-0.51%)
NERV : 2.32 (-1.69%)
ATAI : 1.7400 (-2.79%)
CYBN : 0.3850 (-3.73%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.100 (unch)
SAGE : 43.15 (-0.51%)
NERV : 2.32 (-1.69%)
ATAI : 1.7400 (-2.79%)
CYBN : 0.3850 (-3.73%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.32 (-1.69%)
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

BIIB : 285.94 (-1.43%)
MRNA : 180.87 (-4.48%)
NVAX : 10.65 (-5.67%)
NERV : 2.32 (-1.69%)
RLMD : 4.06 (-1.46%)
Its Been A Slow, But Promising Climb for Minerva Neurosciences

A handful of analysts offering 12-month price forecasts for Minerva Neuroscienes Inc (NASDAQ: NERV) have elected a median price target of $17.

NERV : 2.32 (-1.69%)
NERV Stock Is on the Move, but Is It a Buy?

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash...

BIIB : 285.94 (-1.43%)
INCY : 83.65 (-2.39%)
NERV : 2.32 (-1.69%)
TAIPY : 10.4200 (+0.03%)
Stock Indexes Sink on Fed Policy Outlook

Morning Markets September S&P 500 futures (ESU22 ) this morning are down -0.73% at a 1-month low. Stock indexes this morning are extending last Friday’s rout after Fed Chair Powell signaled the Fed...

ESH23 : 4,028.25 (-0.11%)
AMZN : 100.55 (-1.65%)
AAPL : 143.00 (-2.01%)
GOOGL : 96.94 (-2.45%)
MSFT : 242.71 (-2.20%)
META : 147.06 (-3.08%)
NVDA : 191.62 (-5.91%)
MARA : 7.17 (-10.60%)
MSTR : 245.69 (-4.90%)
BTBT : 1.4400 (-1.37%)
COIN : 56.16 (-8.49%)
RIOT : 5.94 (-6.16%)
Minerva Neurosciences up More Than 100% This Week, but Is It a Better Pick Than Vertex Pharma?

Minerva Neurosciences (NERV) and Vertex Pharmaceuticals (VRTX) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the industry. Since NERV has...

NERV : 2.32 (-1.69%)
VRTX : 319.98 (-0.46%)
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

JNJ : 162.00 (-3.70%)
RPRX : 38.64 (-0.67%)
NERV : 2.32 (-1.69%)
AERI : 15.25 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

3rd Resistance Point 2.66
2nd Resistance Point 2.59
1st Resistance Point 2.45
Last Price 2.32
1st Support Level 2.24
2nd Support Level 2.17
3rd Support Level 2.03

See More

52-Week High 15.27
Fibonacci 61.8% 9.92
Fibonacci 50% 8.27
Fibonacci 38.2% 6.61
Last Price 2.32
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar